SEOM clinical guidelines for the treatment of Hodgkins lymphoma
Clin. transl. oncol. (Print)
; 17(12): 1005-1013, dic. 2015. tab, ilus
Article
in En
| IBECS
| ID: ibc-147439
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10-15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT (AU)
RESUMEN
No disponible
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Spain
/
Therapeutics
/
Hodgkin Disease
/
Lymphocytes
/
Cell Transplantation
/
Biopsy, Fine-Needle
/
Lymph Nodes
/
Lymphatic Diseases
Type of study:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2015
Document type:
Article